Resultados de Búsqueda
There is no evidence that the usage of antimicrobian mouthwashers and nasal sprays by patients who are having an aerosol-generating procedure are avoiding the infection of healthcare workers, whether ...
Evidencias COVID-19
Cochrane - Revisión sistemática
There is currently no evidence of the benefits and risks of patients using antimicrobial mouthwashes or nasal sprays to protect workers performing aerosol-generating procedures in patients without known or suspected COVID-19 infection. Further studies are to be performed to shed light on the measures.
ver más ... 2020The use of naftidrofuryl has shown more risks than benefits for intermittent claudication associated with peripheral arterial disease.
Prescrire bilan. Towards better patient care: drugs to avoid
Prescrire International
Naftidrofuryl is a vasodilator that was licensed for intermittent claudication associated with peripheral arterial disease, increasing walking distance by a few dozen meters, but can cause headache, esophagitis, mouth ulceration, skin disorders, kidney stones and potentially serious liver disorders. A walking exercise program is an effective treatment with less risk.
ver más ... 2020The use of ertugliflozin has shown more risk than benefit in patients with type II diabetes.
Prescrire bilan. Towards better patient care: drugs to avoid
Prescrire International
As of 2019, hypoglycemic drugs belonging to the gliflozin class (sodium-glucose cotransporter 2 inhibitors) have an unfavorable benefit-harm balance in type 2 diabetes. Those currently marketed in Europe are canagliflozin (alone or in combination with metformin), dapagliflozin (alone or in combination with metformin or saxagliptin), empagliflozin (alone or in combination with metformin or linagliptin) and ertugliflozin. However, gliflozins are not included in the 2020 list of drugs to avoid, ...
ver más ... 2020The use of dapagliflozin has shown more risk than benefit in patients with type II diabetes.
Prescrire bilan. Towards better patient care: drugs to avoid
Prescrire International
As of 2019, hypoglycemic drugs belonging to the gliflozin class (sodium-glucose cotransporter 2 inhibitors) have an unfavorable benefit-harm balance in type 2 diabetes. Those currently marketed in Europe are canagliflozin (alone or in combination with metformin), dapagliflozin (alone or in combination with metformin or saxagliptin), empagliflozin (alone or in combination with metformin or linagliptin) and ertugliflozin. However, gliflozins are not included in the 2020 list of drugs to avoid, ...
ver más ... 2020Convalescent plasma therapy added to standard treatment has not shown significant improvements in time to clinical improvement among patients with severe or life-threatening COVID-19.
Evidencias COVID-19
IHCAI – DIME. Información seleccionada sobre intervenciones para el tratamiento de COVID-19
One RCT and four non-randomized studies were included in this report, providing limited quality evidence regarding the clinical effectiveness of convalescent plasma (CP) therapy added to standard treatment, compared to standard treatment alone, in adults with COVID - 19 serious or life threatening. CP therapy did not significantly improve the time to clinical improvement in 28 days. No evidence was found regarding the effectiveness of CP therapy in pediatric populations, the effectiveness of CP ...
ver más ... 2020